SMLR - Semler Scientific down 10% following Q1 bottom and top line misses

Shares of Semler Scientific (NASDAQ:SMLR) dropped 10% in post-market trading after the healthcare technology products company reported Q1 2021 earnings that missed on the top and bottom lines. Q1 GAAP EPS of $0.41 missed by $0.07 while revenue of ~$14M, a 6.2% year-over-year increase, missed by ~$500K. Net income in the quarter of $3.4M was a ~31% decline from Q1 2021. Semler was impacted in Q1 by a 41% increase in total operating expenses -- including cost of revenues -- to $10.1M. The company ended the quarter with $38.4M in cash. Looking ahead, Semler (SMLR) issued 2022 guidance of revenue between $58M and $60M, and operating expenses between $44M and $46M. Read why Seeking Alpha contributor Aamir Jaffer considers Semler (SMLR) a buy.

For further details see:

Semler Scientific down 10% following Q1 bottom and top line misses